Pure Global AI
NCT06365216Not yet recruiting

ALS Phase II Study of NX210c

A Double-blind, Randomized, Placebo-controlled, Multicentric, Phase II Study in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Infusions of NX210c
Axoltis PharmaPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Amyotrophic Lateral Sclerosis
Drug/Device/Intervention
NX210c
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Axoltis Pharma
Location
Bron, France
Timeline & enrollment
Phase
Phase 2
Start date
Sep 01, 2024
End date
Feb 01, 2026
Enrollment
80 participants
Primary outcome

The effect of NX210c on blood neurofilament light chain (NfL) or on a blood and cerebrospinal fluid (CSF) biomarker of BBB integrity.

Summary

This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of
 multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic
 lateral sclerosis (ALS).

ICD-10 classifications
Neuralgic amyotrophyMotor neuron diseaseOther degenerative diseases of the nervous systemOther degenerative disorders of nervous system in diseases classified elsewhereMultiple sclerosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06365216
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06365216 through Pure Global AI's free database. This Phase 2 trial is sponsored by Axoltis Pharma and is currently Not yet recruiting. The study focuses on Amyotrophic Lateral Sclerosis. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.